SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, October 12, 2023

Information

Tags:

Symantec Endpoint Protection, Law officers of the Crown, FDA, Food and Drug Administration, News, Vincent Wong, Food, CRL, Allergy, Adrenaline, Law, ARS, Pharmaceutical industry

Geotags:

NEW YORK, NY, US

⚠ partially generated by AI ↴

Organisation:

LAW OFFICES OF VINCENT WONG, THE LAW OFFICES OF VINCENT WONG

Stock Symbol:

NasdaqGM:SPRY

Summary

Key Points:

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:
The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and directors regarding potential securities fraud.
The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders:

The Law Offices of Vincent Wong announce that an investigation has commenced into ARS and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below:

On September 19, 2023, ARS announced it received from the Food and Drug Administration (FDA) a Complete Response Letter (CRL) concerning ARS’ “neffy.” “Neffy” is a nasally administered epinephrine dose used in cases of severe allergic reactions. The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval. In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions. Following this news, ARS’ stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share.

If you suffered a loss on your investment in ARS, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/ars-class-action-submission-form/?prid=51252&wire=3

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: [email protected]